RCKT Rocket Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

RCKT [NASD]

Rocket Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.60	Insider Own	2.10%	Shs Outstand	54.88M	Perf Week	0.22%
Market Cap	1.13B	Forward P/E	-	EPS next Y	-1.94	Insider Trans	0.10%	Shs Float	50.18M	Perf Month	22.76%
Income	-82.50M	PEG	-	EPS next Q	-0.51	Inst Own	98.00%	Short Float	16.52%	Perf Quarter	42.32%
Sales	-	P/S	-	EPS this Y	16.70%	Inst Trans	3.50%	Short Ratio	18.46	Perf Half Y	-8.61%
Book/sh	5.21	P/B	4.34	EPS next Y	1.50%	ROA	-24.40%	Target Price	36.00	Perf Year	70.57%
Cash/sh	5.50	P/C	4.11	EPS next 5Y	10.80%	ROE	-30.70%	52W Range	9.01 - 27.59	Perf YTD	-0.70%
Dividend	-	P/FCF	-	EPS past 5Y	14.60%	ROI	-	52W High	-18.09%	Beta	2.12
Dividend %	-	Quick Ratio	13.30	Sales past 5Y	-	Gross Margin	-	52W Low	150.83%	ATR	1.63
Employees	72	Current Ratio	13.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	57.69	Volatility	8.82% 7.93%
Optionable	Yes	Debt/Eq	0.23	EPS Q/Q	-4.20%	Profit Margin	-	Rel Volume	0.91	Prev Close	23.68
Shortable	Yes	LT Debt/Eq	0.23	Earnings	-	Payout	-	Avg Volume	449.11K	Price	22.60
Recom	1.50	SMA20	7.20%	SMA50	16.62%	SMA200	24.64%	Volume	406,859	Change	-4.56%

Jul-02-20

Initiated

JP Morgan

Overweight

Jun-25-20

Resumed

BofA/Merrill

Buy

$34

Jun-01-20

Resumed

Oppenheimer

Outperform

Nov-06-19

Initiated

Chardan Capital Markets

Buy

$30

Sep-26-19

Initiated

Piper Jaffray

Overweight

Apr-23-19

Initiated

Robert W. Baird

Outperform

Mar-15-19

Initiated

BofA/Merrill

Buy

$27

Feb-05-19

Initiated

Oppenheimer

Outperform

$39

Sep-13-18

Initiated

Ladenburg Thalmann

Buy

$30

Jul-10-18

Initiated

William Blair

Outperform

Jul-08-20 12:53PM	J.P. Morgan Says These 3 Stocks Will Surge Over 30% From Current Levels TipRanks +6.65%
Jun-29-20 07:00AM	Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis Business Wire
Jun-27-20 03:16PM	Hedge Funds Arent Crazy About Rocket Pharmaceuticals, Inc. (RCKT) Anymore Insider Monkey
Jun-08-20 07:00AM	Rocket Pharmaceuticals Announces Private Exchange Transaction Regarding Its Outstanding Convertible Senior Notes due 2021 Business Wire
May-26-20 07:00AM	Rocket Pharmaceuticals Announces Participation at the Jefferies Virtual Healthcare Conference Business Wire
May-12-20 07:00AM	Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy Business Wire
May-10-20 10:39PM	Was The Smart Money Right About Rocket Pharmaceuticals (RCKT)? Insider Monkey
May-06-20 07:00AM	Rocket Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Progress Business Wire
May-05-20 07:00AM	Rocket Pharmaceuticals Announces Participation at the BofA Securities 2020 Health Care Conference Business Wire +9.18%
Apr-22-20 07:00AM	Rocket Pharmaceuticals Appoints Elisabeth Bjrk, M.D., Ph.D. to Board of Directors Business Wire
Apr-09-20 08:22AM	Rocket Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-02-20 09:00AM	Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic Business Wire +6.46%
Mar-27-20 10:04AM	Why Rocket (RCKT) Stock Might be a Great Pick Zacks -9.48%
Mar-19-20 07:00AM	Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease Business Wire +32.85%
Mar-05-20 07:00AM	Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights Business Wire
Feb-24-20 07:00AM	Rocket Pharmaceuticals Announces Publication of Manuscript Evaluating Mosaicism in Fanconi Anemia Business Wire
Feb-18-20 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Feb-11-20 09:15AM	Rocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021 Business Wire
Feb-06-20 07:00AM	Rocket Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Awareness Business Wire
Jan-09-20 09:44AM	What You Must Know About Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) Beta Value Simply Wall St.
Jan-06-20 12:00PM	Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to Buy Zacks
07:00AM	Rocket Pharmaceuticals Announces Participation at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-29-19 03:24AM	Corporate Insiders Pull the Trigger on 3 Buy-Rated Stocks TipRanks
Dec-16-19 07:00AM	Rocket Pharmaceuticals Receives the European Medicines Agency PRIME Eligibility for RP-L102 Gene Therapy for Fanconi Anemia Business Wire +7.26%
Dec-13-19 04:01PM	Rocket Pharmaceuticals Announces Closing of Public Offering Business Wire
12:37PM	Did Hedge Funds Drop The Ball On Rocket Pharmaceuticals, Inc. (RCKT) ? Insider Monkey
Dec-11-19 07:21AM	The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga -13.99%
Dec-10-19 10:45PM	Rocket Pharmaceuticals Prices Public Offering of Common Stock Business Wire +5.44%
04:01PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
12:00PM	Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to Buy Zacks
07:56AM	The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Benzinga
Dec-09-19 07:00AM	Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I Business Wire
Dec-08-19 06:00PM	Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 "Process B" for Fanconi Anemia at 61st American Society of Hematology Annual Meeting Business Wire
Dec-06-19 07:00AM	Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 "Process B" for Fanconi Anemia Business Wire +13.47%
Dec-05-19 07:00AM	Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting Business Wire
Dec-04-19 09:27AM	Rocket Pharmaceuticals, Inc. (RCKT) Shares March Higher, Can It Continue? Zacks
Nov-27-19 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences TEST Business Wire Releases
Nov-07-19 07:00AM	Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights Business Wire
Nov-06-19 09:00AM	Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 Process B for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting Business Wire
Nov-05-19 07:00AM	Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit Business Wire
Nov-01-19 11:16AM	Should You Buy Rocket Pharmaceuticals, Inc. (RCKT)? Insider Monkey
Oct-24-19 07:00AM	Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 Process A for Fanconi Anemia Business Wire
Oct-22-19 07:00AM	Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency Business Wire
Oct-15-19 07:00AM	Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress Business Wire +8.24%
Oct-01-19 07:00AM	Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference Business Wire
Sep-23-19 07:00AM	Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency Business Wire
Sep-10-19 07:00AM	Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine Business Wire +5.96%
Sep-04-19 07:00AM	Rocket Pharmaceuticals Announces Registration-Enabling Phase 2 Plans for RP-L102 Gene Therapy for Fanconi Anemia Following a Supportive End-of-Phase 1 FDA Meeting Business Wire
Aug-28-19 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Aug-22-19 07:00AM	Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia Business Wire
Aug-07-19 07:00AM	Rocket Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights Business Wire
Jul-31-19 07:00AM	Rocket Pharmaceuticals Announces Participation at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference Business Wire
Jun-25-19 09:24PM	Heres What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT) Insider Monkey
11:30AM	A Look At The Fair Value Of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Simply Wall St.
Jun-18-19 07:00AM	Rocket Pharmaceuticals Announces Patient Dosing Has Commenced in Phase 1 Clinical Trial of RP-A501, the First Gene Therapy to Treat a Monogenic Heart Failure Syndrome Business Wire
May-29-19 10:00AM	Rocket Pharmaceuticals Sponsors 3rd Annual PKD Patients Forum Business Wire
May-23-19 03:00PM	Did You Manage To Avoid Rocket Pharmaceuticals's (NASDAQ:RCKT) 19% Share Price Drop? Simply Wall St.
May-09-19 01:54PM	Heres What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT) Insider Monkey
May-08-19 07:13AM	Rocket Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM	Rocket Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights Business Wire
May-07-19 07:00AM	Rocket Pharmaceuticals Announces Participation at the Bank of America Merrill Lynch 2019 Healthcare Conference Business Wire
May-02-19 07:00AM	Rocket Pharmaceuticals Presents Preclinical Data of RP-A501 for Danon Disease at the American Society of Gene and Cell Therapy 2019 Annual Meeting Business Wire
Apr-30-19 07:00AM	Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM) Business Wire -6.31%
Apr-18-19 11:20AM	Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares Business Wire
Apr-16-19 08:10AM	The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives Benzinga
Apr-15-19 10:36PM	Rocket Pharmaceuticals Prices Public Offering of Common Stock Business Wire
04:01PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
12:49PM	Rocket Pharmaceuticals Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting Business Wire
Mar-15-19 08:00AM	Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting Business Wire +5.43%
Mar-12-19 07:22AM	Are Insiders Selling Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock? Simply Wall St.
07:00AM	Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S. Business Wire
Mar-11-19 07:00AM	Rocket Pharmaceuticals Sponsors Clinical Trial at University of California, Los Angeles (UCLA) Business Wire +5.52%
Mar-07-19 07:00AM	Rocket Pharmaceuticals Reports Full Year 2018 Financial Results and Operational Highlights Business Wire -5.58%
Mar-05-19 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire -6.42%
Feb-28-19 08:00AM	Rocket Pharmaceuticals Recognizes Rare Disease Day® 2019 Business Wire
Feb-26-19 07:00AM	Rocket Pharmaceuticals Announces Publication of Comprehensive Review of Danon Disease Cases in the International Journal of Cardiology Business Wire
Feb-20-19 07:00AM	Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference Business Wire
Jan-22-19 07:00AM	Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease Business Wire -5.71%
Dec-21-18 07:00AM	Rocket Pharmaceuticals to Join NASDAQ Biotechnology Index Business Wire -7.66%
Nov-30-18 12:00PM	Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares Business Wire
Nov-28-18 01:05PM	Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga
Nov-27-18 08:02PM	Rocket Pharmaceuticals Prices Public Offering of Common Stock Business Wire
08:37AM	Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher Zacks
07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia Business Wire
Nov-26-18 04:15PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire +7.16%
08:36AM	Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome Business Wire
08:36AM	Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector Business Wire
08:36AM	REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector PR Newswire
Nov-25-18 04:00PM	Rocket Pharmaceuticals to Host Conference Call to Reveal First AAV Gene Therapy Program Business Wire
Nov-19-18 07:00AM	Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I) Business Wire
Nov-07-18 07:01AM	Rocket Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights Business Wire
07:00AM	Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia Business Wire
Nov-01-18 09:08AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire +6.69%
Oct-19-18 07:00AM	Rocket Pharmaceuticals Presents Preclinical Data at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) Business Wire
Oct-18-18 07:00AM	Rocket Pharmaceuticals Presents Updated Long-Term Phase 1/2 Clinical Data of RP-L102 in Fanconi Anemia Patients at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) Business Wire -9.84%
Sep-25-18 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Business Wire
Aug-30-18 07:00AM	Rocket Pharmaceuticals Announces Participation at Upcoming Investor Conferences Business Wire
Aug-08-18 07:32AM	Rocket Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:00AM	Rocket Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights Business Wire
Jun-22-18 07:00AM	Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes Business Wire

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shah Gaurav	President & CEO	Mar 24	Option Exercise	0.43	90,925	39,098	1,061,642	Mar 26 07:48 PM
Patel Kinnari	Chief Operating Officer	Mar 18	Buy	9.50	1,000	9,500	6,675	Mar 19 07:56 PM
Shah Gaurav	President & CEO	Feb 25	Option Exercise	0.43	290,000	125,628	976,950	Feb 27 05:36 PM
RTW INVESTMENTS, LP	Director	Dec 10	Buy	22.25	225,000	5,006,250	17,282,324	Dec 12 03:43 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience